HomeCompareAXXTF vs ABBV

AXXTF vs ABBV: Dividend Comparison 2026

AXXTF yields 3.39% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AXXTF wins by $315.5K in total portfolio value· pulled ahead in Year 5
10 years
AXXTF
AXXTF
● Live price
3.39%
Share price
$0.59
Annual div
$0.02
5Y div CAGR
53.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$417.8K
Annual income
$232,140.69
Full AXXTF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AXXTF vs ABBV

📍 AXXTF pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAXXTFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AXXTF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AXXTF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AXXTF
Annual income on $10K today (after 15% tax)
$287.89/yr
After 10yr DRIP, annual income (after tax)
$197,319.59/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, AXXTF beats the other by $176,263.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AXXTF + ABBV for your $10,000?

AXXTF: 50%ABBV: 50%
100% ABBV50/50100% AXXTF
Portfolio after 10yr
$260.1K
Annual income
$128,456.22/yr
Blended yield
49.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AXXTF
No analyst data
Altman Z
1.1
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AXXTF buys
0
ABBV buys
0
No recent congressional trades found for AXXTF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAXXTFABBV
Forward yield3.39%3.06%
Annual dividend / share$0.02$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR53.5%40.6%
Portfolio after 10y$417.8K$102.3K
Annual income after 10y$232,140.69$24,771.77
Total dividends collected$377.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AXXTF vs ABBV ($10,000, DRIP)

YearAXXTF PortfolioAXXTF Income/yrABBV PortfolioABBV Income/yrGap
1$11,220$519.90$11,550$430.00$330.00ABBV
2$12,842$836.82$13,472$627.96$630.00ABBV
3$15,115$1,374.05$15,906$926.08$791.00ABBV
4$18,493$2,320.08$19,071$1,382.55$578.00ABBV
5← crossover$23,860$4,072.21$23,302$2,095.81+$558.00AXXTF
6$33,067$7,537.23$29,150$3,237.93+$3.9KAXXTF
7$50,367$14,985.34$37,536$5,121.41+$12.8KAXXTF
8$86,638$32,744.69$50,079$8,338.38+$36.6KAXXTF
9$173,505$80,802.20$69,753$14,065.80+$103.8KAXXTF
10$417,791$232,140.69$102,337$24,771.77+$315.5KAXXTF

AXXTF vs ABBV: Complete Analysis 2026

AXXTFStock

Axiata Group Berhad, an investment holding company, provides telecommunications services in Asia. The company provides mobile services and other services, such as provision of interconnect services, sale of devices, pay television transmission, and broadband services; and telecommunication infrastructure and related services. The company also offers telecommunication network capacity; international carrier and enterprise; technical and operations support; media and digital; software development; multimedia; data and backbone and fixed wireless; television broadcasting and direct-to home satellite pay television; and financial services, as well as commerce distribution business and rendering solutions. In addition, it is involved in the provision of services related to IT; venture capital funding; network development, operations, and maintenance; digital credit facilities; software licensing; e-learning content; and trading and distribution of communication devices and goods, as well as managing retail stores. Further, the company provides e-commerce and digital marketing; fiber optic transmission networks; multimedia advertising; online ticketing; micro-financing and insurance, and money lending; e-wallet mobile application; and data processing and management consultation services, as well as mobile virtual network enabler platforms, and marketable securities. Additionally, it is also involved in the property development and letting of property for commercial purposes; sale of IT enabled equipment; provision of manpower for call center operations; development and operation of electronic commerce infrastructure for the healthcare sector; provision of IT, information, and communications technology services to nonmobile network operator business activities. The company was formerly known as TM International Berhad and changed its name to Axiata Group Berhad in March 2009. Axiata Group Berhad was incorporated in 1992 and is headquartered in Kuala Lumpur, Malaysia.

Full AXXTF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AXXTF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AXXTF vs SCHDAXXTF vs JEPIAXXTF vs OAXXTF vs KOAXXTF vs MAINAXXTF vs JNJAXXTF vs MRKAXXTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.